Association between antiepileptic drug switching and epilepsy-related events

Epilepsy and Behavior

Volumn 15, Issue 4, 2009, Pages 481-485

  Hansen, Ryan N ^a   Campbell, Jonathan D ^a   Sullivan, Sean D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antiepileptic drugs; Drug therapy; Generic switching; Narrow therapeutic index; Therapeutic substitution

Indexed keywords

CARBAMAZEPINE; CLONAZEPAM; GABAPENTIN; GENERIC DRUG; LAMOTRIGINE; PHENYTOIN; PRIMIDONE; VALPROIC ACID; ZONISAMIDE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMERGENCY CARE; EPILEPSY; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HOSPITALIZATION; HUMAN; INTRACTABLE EPILEPSY; PATIENT COUNSELING;

ADOLESCENT; ADULT; ANTICONVULSANTS; CASE-CONTROL STUDIES; CHEMISTRY, PHARMACEUTICAL; CHILD; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; SEIZURES; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67849099089     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2009.05.019     Document Type: Article

References (24)

1. Epilepsy at a glance. Centers for Disease Control and Prevention, ; 2008 [accessed 22.06.08].
2. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; July 2002.
3. Gilman J.T., Alvarez L.A., and Duchowny M. Carbamazepine toxicity resulting from generic substitution. Neurology 43 (1993) 2696-2697
4. MacDonald J.T. Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology 37 (1987) 1885
5. Welty T.E., Pickering P.R., Hale B.C., and Arazi R. Loss of seizure control associated with generic substitution of carbamazepine. Ann Pharmacother 26 (1992) 775-777
6. Tyrer J.H., Eadie M.J., Sutherland J.M., and Hooper W.D. Outbreak of anticonvulsant intoxication in an Australian city. Br Med J 4 (1970) 271-273
7. Burkhardt R.T., Leppik I.E., Blesi K., et al. Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Neurology 63 (2004) 1494-1496
8. Mikati M., Bassett N., and Schachter S. Double-blind randomized study comparing brand-name and generic phenytoin monotherapy. Epilepsia 33 (1992) 359-365
9. Christopher A., Levine M., and Mcconnell D. A comparison of two brands of carbamazepine in young patients with epilepsy. Can J Hosp Pharm 46 (1993) 67-71
10. Jumao-as A., Bella I., Craig B., Lowe J., and Dasheiff R.M. Comparison of steady-state blood levels of two carbamazepine formulations. Epilepsia 30 (1989) 67-70
11. Berg M.J., Gross R.A., Tomaszewski K.J., Zingaro W.M., and Haskins L.S. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 71 (2008) 525-530
12. Makus K.G., and McCormick J. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. Clin Therap 29 (2007) 334-341
13. Andermann F., Duh M.S., Gosselin A., and Paradis P.E. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 48 (2006) 464-469
14. LeLorier J., Duh M.S., Paradis P.E., et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 70 (2008) 2179-2186
15. Lelorier J, Duh MS, Paradis PE, et al. The risks of multiple generic substitution of antiepileptic drugs: the case of topirimate. International Society for Pharmacoecomonics and Outcomes Research, 13th annual international meeting abstracts; 2008.
16. Kramer G., Biraben A., Carreno M., et al. Current approaches to the use of generic antiepileptic drugs. Epilepsy Behav 11 (2007) 46-52
17. Crawford P., Feely M., Guberman A., and Kramer G. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure 15 (2006) 165-176
18. Borgherini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Therap 25 (2003) 1578-1592
19. Zachry III W.M., Doan Q.D., Clewell J.D., and Smith B.J. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia 50 (2009) 493-500
20. French J.A., and Pedley T.A. Clinical practice. Initial management of epilepsy. N Engl J Med 359 (2008) 166-176
21. Bergstralh EJ, Kosanke JL. Computerized matching of controls. Section of Biostatistics Technical Report 56. Mayo Foundation; 1995.
22. SAS Software, Version 9.1 of the SAS System for Windows. Cary, NC: SAS Institute Inc.; 2002-2003.
23. Koepsell T.D., and Weiss N.S. Epidemiologic methods: studying the occurrence of illness (2003), Oxford Univ. Press, New York
24. Haskins L.S., Tomaszewski K.J., and Crawford P. Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy. Epilepsy Behav 7 (2005) 98-105